Financial reports
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
ARS
2022 FY
Annual report to shareholders
26 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
28 Jul 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
14 Feb 22
Current reports
8-K
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
1 Apr 24
8-K
GRI Bio Announces Pricing of $5.5 Million Public Offering
2 Feb 24
8-K
GRI Bio Announces Reverse Stock Split
30 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
19 Jan 24
8-K
Regulation FD Disclosure
16 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5 Jan 24
8-K
Clinical development plan potentially leveraging 505(b)(2) regulatory pathway
5 Dec 23
8-K
Clinical development plan leveraging 505(b)(2) regulatory pathway
27 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 Nov 23
8-K
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis ("IPF") on track to start before year end 2023; Interim data expected H1 2024
15 Nov 23
Registration and prospectus
424B3
Prospectus supplement
28 Mar 24
424B3
Prospectus supplement
28 Mar 24
424B3
Prospectus supplement
2 Feb 24
424B4
Prospectus supplement with pricing info
2 Feb 24
S-1/A
IPO registration (amended)
31 Jan 24
S-1/A
IPO registration (amended)
30 Jan 24
424B3
Prospectus supplement
30 Jan 24
424B3
Prospectus supplement
19 Jan 24
424B3
Prospectus supplement
5 Jan 24
S-1
IPO registration
21 Dec 23
Proxies
DEFA14A
Additional proxy soliciting materials
5 Jan 24
DEF 14A
Definitive proxy
29 Dec 23
PRE 14A
Preliminary proxy
20 Dec 23
DEFA14A
Additional proxy soliciting materials
26 May 23
DEF 14A
Definitive proxy
26 May 23
DEFA14A
Additional proxy soliciting materials
5 Apr 23
DEFA14A
Additional proxy soliciting materials
4 Apr 23
DEFA14A
Additional proxy soliciting materials
3 Apr 23
DEFA14A
Additional proxy soliciting materials
30 Mar 23
DEFA14A
Additional proxy soliciting materials
23 Mar 23
Other
EFFECT
Notice of effectiveness
2 Feb 24
CORRESP
Correspondence with SEC
30 Jan 24
CORRESP
Correspondence with SEC
30 Jan 24
UPLOAD
Letter from SEC
26 Dec 23
EFFECT
Notice of effectiveness
18 Dec 23
CORRESP
Correspondence with SEC
14 Dec 23
CORRESP
Correspondence with SEC
4 Dec 23
UPLOAD
Letter from SEC
21 Nov 23
EFFECT
Notice of effectiveness
8 Jun 23
CORRESP
Correspondence with SEC
5 Jun 23
Ownership
SC 13G/A
Altium Capital Management LP
13 Feb 24
4
Leanne Kelly
26 Sep 23
4
David Leslie Szekeres
14 Aug 23
4
CAMILLA V SIMPSON
14 Aug 23
4
Roelof Rongen
14 Aug 23
4
David Charles Baker
14 Aug 23
SC 13G
Altium Capital Management LP
3 May 23
SC 13G
TEP Biotech, LLC
2 May 23
SC 13D
Chaturvedi Vipin
25 Apr 23
SC 13D
Agro Albert
25 Apr 23